a

MW x10-3

![](_page_0_Figure_1.jpeg)

HASUMI ET AL

![](_page_0_Figure_2.jpeg)

FIGURE 1 - Combination of VEGFR and PDGFR tyrosine kinase inhibits B16 melanoma tumor growth in vive. (a) Subconfluent cultures of PAE/PDGFRβ cells were stimulated with conditioned media from B16/mock or B16/PDGF-BB cells for 1 hr on ice (left panels). Altematively, PAE/PDGFRB cells were incubated for 5 min at 37ºC with conditioned medium or increasing amounts of PDGF-BB (right panels). PDGFR$ phosphorylation was analyzed by PDGFRβ and phospho-tyrosine (pTyr) immunoblotting of wheat germ agglutinin adsorbed fractions of cell lysates. (b) B16/PDGF-BB cells were seeded in 12-well plates and cultured in the presence of vehicle (�), 3 μM STI571 (●), 1 uM PTK787 (a) or 3 uM ST1571 and 1 μM PTK787 (e). B16/mock (c) or B16/PDGF-BB (d) cells were inoculated subcutaneously to C57Bl6/J mice. When the tumor volume reached 20 mm², mice received either p.o. gavage of vehicle (�), 100 mg/kg/day ST1571 (@), 25 mg/kg/day PTK787 (▲) or 100 mg/kg/day STI571 and 25 mg/kg/day PTK787 (○). Treatment was given for 13 days for mice bearing B16/mock tumors (c) and 8 days for mice bearing B16/PDGF-BB tumors (d). Tumor volumes, determined by palpation were followed over time. Results are presented as mean and S.E.M. Statistical significance was evaluated using a one-way ANOVA followed by post hoc analysis applying the Duncan adjustment. Significance is shown for the last day of treatment: *, p < 0.05 compared to vehicle treatment; §, p < 0.05 compared to PTK787 treatment: #. p < 0.05 compared to STI571 treatment. (e) Sis-NH3T3 tumors treated with vehicle (lanes 2 and 3), a combination of PTK787/ST1571 (25 mg/100 mg/kg/day; lanes 4 and 5), PTK787 (25 mg/kg/day, lanes 6 and 7), STI571 (100 mg/kg/day, lanes 8 and 9) or STI571 (200 mg/kg/ day, lanes 10 and 11). PDGFRS was immunoprecipitated from 15 mg tumor lysate, and receptor phosphorylation was analyzed by PDGFRβ and phospho-tyrosine (pTyr) immunoblotting. Rabbit IgG recognizing PTEN was used for immunoprecipitation as a negative control (lane 1). The ratio between the densitometric analysis of the phosphotyrosine band and the upper, mature PDGFRB band were compared to the first vehicle-treated tumor to obtain the relative receptor phosphorylation.

## Results

## In vitro characterization of a B16F10 melanoma clone which produces PDGF-BB

A B16 melanoma cell line producing PDGF-BB (B16/PDGFlate a clone with robust PDGF-BB production that was selected for further experiments. As shown in Figure 1a (left panels), conditioned medium from the selected B16/PDGF-BB clone, but not from a mock-transfected clone (B16/mock), induced strong PDGFRS phosphorylation in porcine aortic endothelial cells

transfected with the PDGFRS (PAE/PDGFRB), indicating production of a large amount of PDGF-BB. The amount of PDGF-BB released into the conditioned medium was estimated by incubating PAE/PDGFRB cells with either conditioned medium or increasing amounts of PDGF-BB. After 2 days, the B16/PDGF-BB cells had released an amount of PDGF into the medium that was in excess of 0.5 ng/ml PDGF-BB (Fig. 1a, right panels). It should be noted that PDGF-BB sticks to both cells and plastic, so this amount is likely to represent underestimation of the production of PDGF-BB.

